The shares of Walgreens Boots Alliance, Inc. (NASDAQ:WBA) has been pegged with a rating of Neutral by Guggenheim in its latest research note that was published on April 18th, 2019. The research company has also assigned a $59 price target. Guggenheim wasn’t the only research firm that published a report of Walgreens Boots Alliance, Inc., with other equities research analysts also giving their opinion on the stock. Pivotal Research Group advised investors in its research note published on April 3rd, 2019, to Hold the WBA stock while also putting a $60 price target. The stock had earned Hold rating from Loop Capital when it published its report on April 3rd, 2019. The stock was given Underperform rating by BofA/Merrill in its report released on March 8th, 2019, the day when the price target on the stock was placed at $62. UBS was of a view that WBA is Sell in its latest report on January 17th, 2019 while giving it a price target of $70. Wolfe Research thinks that WBA is worth Peer Perform rating. This was contained in the firm’s report on December 19th, 2018.
Amongst the analysts that rated the stock, 1 have recommended investors to sell it, 18 believe it has the potential for further growth, thus rating it as Hold while 1 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $58.47. The price of the stock the last time has raised by 7.63% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 46.64.
The shares of the company added by 2.06% during the trading session on Tuesday, reaching a low of $51.51 while ending the day at $53.07. During the trading session, a total of 5.26 million shares were traded which represents a -3.89% decline from the average session volume which is 5.06M shares. WBA had ended its last session trading at 52.00. Walgreens Boots Alliance, Inc. currently has a market cap of $48.14B, while its P/E ratio stands at 10.79, while its P/E earnings growth sits at 0.35, with a beta of 0.87. Walgreens Boots Alliance, Inc. debt-to-equity ratio currently stands at 0.73, while its quick ratio hovers at 0.40. WBA 52-week low price stands at $49.31 while its 52-week high price is $86.31.
The company in its last quarterly report recorded $1.47 earnings per share which is above the $1.43 predicted by most analysts. The Walgreens Boots Alliance, Inc. generated $34,591.00 million in revenue during the last quarter, which is slightly higher than the $34,456.40 million predicted by analysts. In the second quarter last year, the firm recorded $1.64 earnings per share. Compared to the same quarter last year, the firm’s revenue was down by -11.56%. Walgreens Boots Alliance, Inc. has the potential to record 4.92 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Barclays published a research note on June 11th, 2019 where it informed investors and clients that Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) is now rated as Overweight. Their price target on the stock stands at $10. Pivotal Research Group also rated FOMX as Reiterated on April 3rd, 2019, with its price target of $60 suggesting that FOMX could surge by 80.34% from its current share price. Even though the stock has been trading at $2.68/share, analysts expect it to surge higher by 14.93% to reach $15.67/share. It started the day trading at $3.29 and traded between $2.71 and $3.08 throughout the trading session.
A look at its technical shows that FOMX’s 50-day SMA is 2.44 while its 200-day SMA stands at 3.35. At the moment, only of Foamix Pharmaceuticals Ltd. shares were sold short. The company’s average trading volume currently stands at 500.72K shares, which means that the short-interest ratio is just 4.22 days. Over the past seven days, the company moved, with its shift of 27.27%. Looking further, the stock has raised 18.46% over the past 90 days while it lost -13.24% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. Perceptive Advisors LLC bought more FOMX shares, increasing its portfolio by +140.33% during the last quarter. This move now sees Perceptive Advisors LLC purchasing 6,542,057 shares in the last quarter, thus it now holds 11,203,881 shares of FOMX, with a total valuation of $26,777,276. Great Point Partners LLC followed the path by decreasing its FOMX portfolio by -33.36% in the quarter. This means that Great Point Partners LLC sold -1,350,428 shares in the last quarter and now controls 2,697,133 shares of the FOMX stock, with the valuation hitting $6,446,148.
The firm sold 0 shares during the quarter which decreased its stakes to 1,350,938 shares and is now valued at $3,228,742. Following these latest developments, around 1.00% of Foamix Pharmaceuticals Ltd. stocks are owned by institutional investors and hedge funds.